Minimal Residual Disease in Melanoma Biology, Detection and Clinical Relevance
Knowledge about diagnostic procedures in melanoma has in creased rapidly within the past few years. Single tumor cells have been identified in normal tissue such as sentinel lymph nodes, as well as in bone marrow, peripheral blood, and other bodily fluids and cells, by molecular technologies. The i...
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2001, 2001
|
| Edition: | 1st ed. 2001 |
| Series: | Recent Results in Cancer Research
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- I Biology of Micrometastases and Advances in Methods for Detection
- The Biology of Melanoma Micrometastases
- Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping
- Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells
- Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems
- Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients
- Rapid Enrichment and Detection of Melanoma Cells from PBMC by a New Assay Combining Immunomagnetic Cell Sorting and Immunocytochemical Staining
- II. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow
- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection of Melanoma-Related Transcripts in the Peripheral Blood and Bone Marrow of Patients with Malignant Melanoma. What Have We Learned?
- The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma
- Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients
- Facts and Pitfalls in the Detection of Tyrosinase mRNA in the Blood of Melanoma Patients by RT-PCR
- Morphologically Intact Melanoma Cells May Be Detected in Peripheral Blood of Melanoma Patients
- Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time
- III. Detection of Minimal Residual Disease in Sentinel Nodes
- The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas
- Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma
- IV. Early Recognition and Monitoring by Serological Markers
- Monitoring Malignant Melanoma with the S-100B Tumour Marker
- Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma
- Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients
- V. Clinical Relevance of Micrometastases Detection
- Molecular Tools in the Detection of Micrometastatic Cancer Cells — Technical Aspects and Clinical Relevance
- The Clinical Relevance of Molecular Staging for Melanoma
- Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients
- Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness
- VI. Therapeutic Strategies Against Residual Melanoma Cells
- Utility of Tests for Circulating Melanoma Cells in Identifying Patients Who Develop Recurrent Melanoma
- Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen
- Autologous Dendritic Cells for Treatment of Advanced Cancer — An Update
- A Novel Strategy in the Elimination of Disseminated Melanoma Cells: Chimeric Receptors Endow T Cells with Tumor Specificity